References

1. ALDA M: Pharmacogenetics of lithium response in bipolar disorder. J Psychiatry Neurosci, 24:154-158, 1999. [ Links ]

2. ANISMAN H, KOKKINIDIS L, MERALI Z: Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun, 16:544-56, 2002. [ Links ]

3. ANISMAN H , RAVINDRAN AV, GRIFFITHS J, MERALI Z : Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry, 4:182-8, 1999. [ Links ]

4. ANSARI-LARI M, MUZNY D, LU J, LU F et al.: A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13. Genome Res, 6:314-326, 1996. [ Links ]

5. ARIAS B, CATALAN R, GASTO C, GUTIERREZ B, FANANAS L: 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol, 23:563-7, 2003. [ Links ]

6. ARIAS B , CATALAN R , GASTO C , GUTIERREZ B , FANANAS L : Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol, 19:166-172, 2005. [ Links ]

7. ARIAS B , SERRETT A, LORENZI C, GASTO C et al.: Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord, 90:251-256, 2006. [ Links ]

8. ARINAMI T, LI L, MITSUSHIO H, ITOKAWA M et al.: An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol Psychiatry, 40:1122-7, 1996. [ Links ]

9. ARRANZ ESTEVEZ FJ: The modulatory role of neurokinins in affective behaviors. Actas Esp Psiquiatr, 33:55-65, 2005. [ Links ]

10. BAGHAI T, SCHULE C, ZWANZGER P, MINOV C et al.: Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. Neurosci Lett, 328:299-303, 2002. [ Links ]

11. BAGHAI T , SCHULE C , ZWANZGER P , ZILL P et al.: Influence of a functional polymorphism within the angiotensin I-converting enzyme gene on partial sleep deprivation in patients with major depression. Neurosci Lett, 339:223-226, 2003. [ Links ]

12. BAGHAI T C, SCHULE C , ZILL P , DEIML T et al.: The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett, 363:38-42, 2004. [ Links ]

13. BAGHAI T C, SCHULE C , ZWANZGER P , MINOV C et al.: Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry , 6:258-9, 2001. [ Links ]

14. BAILEY D, BONDAR A, FURNESS L: Pharmacogenomics-it's not just pharmacogenetics. Curr Opin Biotechnol, 9:596-601, 1998. [ Links ]

15. BARTLETT CW, GHARANI N, MILLONIG JH, BRZUSTOWICZ LM: Three autism candidate genes: a synthesis of human genetic analysis with other disciplines. Int J Dev Neurosci, 23:221-34, 2005. [ Links ]

16. BELLIVIER F, CHASTE P, MALAFOSSE A: Association between the TPH gene A218C polymorphism and suicidal behavior: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet, 124:87-91, 2004. [ Links ]

17. BELLIVIER F , LEROUX M, HENRY C, RAYAH F et al.: Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neuroscience Letters, 334:17-20, 2002. [ Links ]

18. BENEDETTI F, SERRETTI A, COLOMBO C, BARBINI B et al.: Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet, 123B:23-6, 2003. [ Links ]

19. BERTILSSON L, DAHL M, DALEN P, AL-SHURBAJI A: Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol, 53:111-122, 2002. [ Links ]

20. BINDER E, SALYAKINA D, LICHTNER P, WOCHNIK G et al.: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet, 36:1319-1325, 2004. [ Links ]

21. BOBB AJ, CASTELLANOS FX, ADDINGTON AM, RAPOPORT JL: Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B Neuropsychiatr Genet , 132:109-25, 2005. [ Links ]

22. BOESS F, MONSMA FJ, CAROLO C, MEYER V et al.: Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology, 36:713-720, 1997. [ Links ]

23. BONDY B, BAGHAI T , ZILL P , SCHULE C et al.: Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Prog Neuropsychopharmacol Biol Psychiatry , 29:1094-99, 2005. [ Links ]

24. BONDY M: Pathophysiology of depression and mechanisms of treatment. Dialogues Clinical Neuroscience, 4:21-29, 2002. [ Links ]

25. BOOIJ L, VAN DER DOES A, RIEDEL W: Monoamine depletion in psychiatric and healthy populations: review. Mol Psychiatry , 8:951-973, 2003. [ Links ]

26. BROSEN K, HANSEN J, NIELSEN K: Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol, 44:344-355, 1993. [ Links ]

27. BROSEN K , NARANJO C: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol, 11:275-283, 2001. [ Links ]

28. BROWN PO, BOTSTEIN D: Exploring the new world of the genome with DNA microarrays. Nat Genet , 21:33-7, 1999. [ Links ]

29. CAMPBELL D, SUNDARAMURTHY D, MARKHAM A, PIERI L: Fine mapping of the human 5-HTR2a gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders. Genet Test, 1:297-299, 1997. [ Links ]

30. CASPI A, SUGDEN K, MOFFITT TE, TAYLOR A et al.: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301:386-9, 2003. [ Links ]

31. CASTRO ME, DIAZ A, DEL OLMO E, PAZOS A: Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT(1A) receptors in rat brain. Neuropharmacology , 44:93-101, 2003. [ Links ]

32. CHEN B, WANG J, SUN X, YOUNG L: Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. Biol Psychiatry , 53:530-537, 2003. [ Links ]

33. CHOI M, KANG R, HAM B, JEONG H, LEE M: Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology, 52:155-162, 2005. [ Links ]

34. COURTET P, BAUD P, ABBAR M, BOULENGER JP et al.: Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene. Mol Psychiatry , 6:338-41, 2001. [ Links ]

35. CRAIG SP, BOULARAND S, DARMON MC, MALLET J, CRAIG IW: Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization. Cytogenetics Cell Genetics, 56:157-9, 1991. [ Links ]

36. CRAMER JA, ROSENHECK R: Compliance with medication regimens for mental and physical disorders. Psychiatr Serv, 49:196-201, 1998. [ Links ]

37. CRISSMAN AM, MAKHAY MM, O'DONNELL JM: Discriminative stimulus effects of centrally administered isoproterenol in rats: mediation by beta-1 adrenergic receptors. Psychopharmacology (Berl), 154:70-5, 2001. [ Links ]

38. CUSIN C, SERRETTI A , LATTUADA E, LILLI R et al.: Influence of 5-HTTLPR and TPH Variants on Illness Time Course in Mood Disorders. J Psychiatric Research, 35:217-223, 2001. [ Links ]

39. CUSIN C , SERRETTI A , ZANARDI R, LATTUADA E et al.: Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. International J Neuropsychopharmacology, 5:27-35, 2002. [ Links ]

40. CZEH B, PUDOVKINA O, VAN DER HART M, SIMON M et al.: Examining SLV-323, a novel NK1 receptor antagonist, in a chronic psychosocial stress model for depression. Psychopharmacology (Berl) , 180:548-557, 2005. [ Links ]

41. DALEN P , DAHL M , RUIZ M et al.: 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther, 63:444-452, 1998. [ Links ]

42. DANTZER R, BLUTHE R, GHEUSI G, CREMONA S et al.: Molecular basis of sickness behavior. Ann N Y Acad Sci, 856: 132-138, 1998. [ Links ]

43. DRIGUES N, POLTYREV T, BEJAR C, WEINSTOCK M, YOUDIM M: cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs. J Neural Transm, 110:1413-1436, 2003. [ Links ]

44. DUNN A, SWIERGIEL A, DE BEAUREPAIRE R: Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev, 29:891-909, 2005. [ Links ]

45. ESPOSITO K, GOODNICK P: Predictors of response in depression. Psychiatr Clin North Am, 26:353-365. 2003. [ Links ]

46. FAVA GA, FABBRI S, SONINO N: Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry , 26:1019-1027, 2002. [ Links ]

47. FEINN R, NELLISSERY M, KRANZLER HR: Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet , 133:79-84, 2005. [ Links ]

48. GARRIOCK H, ALLEN J, DELGADO P, NAHAZ Z et al.: Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry , 10:976-977, 2005. [ Links ]

49. GENTSCH C, CUTLER M, VASSOUT A, VEENSTRA S, BRUGGER F: Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils. Behav Brain Res, 133:363-368, 2002. [ Links ]

50. GOODNICK PJ: Predictors of Treatment Response in Mood Disorders. Clinical Practice. American Psychiatric Press, Washington, 1996. [ Links ]

51. GUIARD B, LANFUMEY L, GARDIER A: Microdialysis approach to study serotonin outflow in mice following selective serotonin reuptake inhibitors and substance P (neurokinin 1) receptor antagonist administration: a review. Curr Drug Targets, 7:187-201, 2006. [ Links ]

52. GUTIERREZ B , PINTOR L, GASTO C , ROSA A et al.: Variability in the serotonin transporter gene and increased risk for major depression with melancholia. Hum Gen, 103:319-322, 1998. [ Links ]

53. HAM B , LEE M , LEE H, KANG R et al.: No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet, 15:229-301, 2005. [ Links ]

54. HEALY D, WATERHOUSE J: The circadian system and the therapeutics of the affective disorders. Pharmacol Ther, 65:241-263, 2005. [ Links ]

55. HEILS A, TEUFEL A, PETRI S, STÖBER G et al.: Allelic variation of human serotonin trasporter gene expression. J Neurochem, 66:2621-2624, 1996. [ Links ]

56. HEMRICK-LUECKE SK, SNODDY HD, FULLER RW: Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Iife Sci, 55:479-83, 1994. [ Links ]

57. HOLMES A, MURPHY DL, CRAWLEY JN: Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol Psychiatry , 54:953-9, 2003a. [ Links ]

58. HOLMES A , YANG RJ, LESCH KP, CRAWLEY JN , MURPHY DL : Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology, 28:2077-88, 2003b. [ Links ]

59. HONG C, CHEN T, YU Y, TSAI S: Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J, 6:27-33, 2006. [ Links ]

60. ITO K, YOSHIDA K, SATO K, TAKAHASHI H et al.: A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res, 111:235-9, 2002. [ Links ]

61. JONSSON EG, GOLDMAN D, SPURLOCK G, GUSTAVSSON JP et al.: Tryptophan hydroxylase and catechol-O-methyl-transferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. European Archives Psychiatry Clinical Neuroscience, 247:297-302, 1997. [ Links ]

62. JOYCE PR, MULDER RT, LUTY SE, MCKENZIE JM et al.: Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol, 6:339-46, 2003. [ Links ]

63. KAO C: Functional genomic technologies:creating new paradigms for fundamental and appled biology. Biotechnol Prog, 15:304-311, 1999. [ Links ]

64. KATO M, IKENAGA Y, WAKENO M, OKUGAWA G et al.: Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol, 20:151-156, 2005. [ Links ]

65. KATZENBERG D, YOUNG T, FINN L, LIN L et al.: A Clock polymorphism associated with human diurnal preference. Sleep, 21:569-576, 1998. [ Links ]

66. KIM DK, LIM SW, LEE S, SOHN SE et al.: Serotonin transporter gene polymorphism and antidepressant response. Neuroreport, 11:215-9, 2000. [ Links ]

67. KING DP, VITATERNA MH, CHANG AM, DOVE WF et al.: The mouse Clock mutation behaves as a antimorph and maps within the W19H deletion, distal of Kit. Genetics, 146: 1049-1060, 1997. [ Links ]

68. KIRCHHEINER J, BROSEN K , DAHL ML, GRAM LF et al.: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand, 104:173-92, 2001. [ Links ]

69. KIRIGITI P, YANG YF, LI X, LI B et al.: Rat beta 1-adrenergic receptor regulatory region containing consensus AP-2 elements recognizes novel transactivator proteins. Mol Cell Biol Res Commun, 3:181-92, 2000. [ Links ]

70. KOHEN R, METCALF MA, KHAN N, DRUCK T et al.: Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem , 66:47-56, 1996. [ Links ]

71. KRAFT J, SLAGER S, MCGRATH P, HAMILTON S: Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry , 58:58, 2005. [ Links ]

72. KRAMER M, WINOKUR A, KELSEY J, PRESKORN S et al.: Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology , 29:2, 2004. [ Links ]

73. KREMER I, BACHNER-MELMAN R, RESHEF A, BROUDE L et al.: Association of the serotonin transporter gene with smoking behavior. Am J Psychiatry, 162:924-30, 2005. [ Links ]

74. LACHMAN HM, KELSOE JR, REMICK RA, SADOVNICK AD et al.: Linkage studies suggest a possible locus for bipolar disorder near the velo-cardio-facial syndrome region on chromosome 22. American J Medical Genetics, 74:121-128, 1997. [ Links ]

75. LACHMAN HM , MORROW B, SHPRINTZEN R, VEIT S et al.: Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet , 67:468-72, 1996. [ Links ]

76. LANDGREBE J, WELZL G, METZ T, VAN GAALEN MM et al.: Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J Psychiatr Res, 36:119-29, 2002. [ Links ]

77. LEE HJ, CHA JH, HAM BJ, HAN CS et al.: Association between a G-protein beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J , 4:29-33, 2004. [ Links ]

78. LEE MS, LEE HY, LEE HJ, RYU SH: Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet , 14:111-5, 2004b. [ Links ]

79. LEE S, LEE K, LEE H, HAM B et al.: Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder. Psychiatry Clin Neurosci, 59:140-145, 2005. [ Links ]

80. LEMONDE S, DU L, BAKISH D, HRDINA P, ALBERT PR: Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Psychopharmacology (Berl) , 24:24, 2004. [ Links ]

81. LEMONDE S , TURECKI G, BAKISH D , DU L et al.: Impaired trans-repression at a 5-HT1A receptor gene polimorphism associated with major depression and suicide. J Neurosci, 23:8788-99, 2003. [ Links ]

82. LESCH KP, BALLING U, GROSS J, STRAUSS K et al.: Organization of the human serotonin transporter gene. J Neural Transm Gen Sect, 95:157-62, 1994. [ Links ]

83. LESCH KP , BENGEL D, HEILS A, SABOL SZ et al.: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274:1527-31, 1996. [ Links ]

84. ICINIO J, O'KIRWAN F, IRIZARRY K, MERRIMAN B et al.: Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry , 9:1075-1082, 2004. [ Links ]

85. LIN JH, LU AY: Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet, 35:361-90, 1998. [ Links ]

86. MAES M, MELTZER HY: The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, 933-944, New York, 1995. [ Links ]

87. MALEK Z, DARDENTE H, PEVET P, RAISON S: Tissue-specific expression of tryptophan hydroxylase mRNAs in the rat midbrain: anatomical evidence and daily profiles. Eur J Neurosci , 22:895-901, 2005. [ Links ]

88. MANNISTO P, KAAKKOLA S: Catechol-O-methyl-transferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev, 51:593-628, 2005. [ Links ]

89. MASOLIVER E, MENOYO A, PEREZ V, VOLPINI V et al.: Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr Genet , 16:25-29, 2006. [ Links ]

90. MASON DA, MOORE JD, GREEN SA, LIGGETT SB: A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem, 274:12670-4, 1999. [ Links ]

91. MATSUSHITA S, SUZUKI K, MURAYAMA M, NISHIGUCHI N et al.: Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet , 128:114-7, 2004. [ Links ]

92. MELKE J, LANDEN M, BAGHEI F, ROSMOND R et al.: Serotonin transporter gene polymorphisms are associated with anxiety-related personality traits in women. Am J Med Genet , 105:458-63, 2001. [ Links ]

93. MENESES A. Role of 5-HT6 receptors in memory formation. Drug News Perspect, 14:396-400, 2001. [ Links ]

94. MIGNONE F, GISSI C, LIUNI S, PESOLE G: Untranslated regions of mRNAs. Genome Biol, 3:REVIEWS0004, 2002. [ Links ]

95. MINOV C , BAGHAI T C, SCHULE C , ZWANZGER P et al.: Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett, 303:119-22, 2001. [ Links ]

96. MONCRIEFF J, KIRSCH I: Efficacy of antidepressants in adults. BMJ, 331:551-557, 2005. [ Links ]

97. MULLER DJ, SCHULZE TG, MACCIARDI F, OHLRAUN S et al.: Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase-A promoter Eighth World Congress on Psychiatric Genetics. Vol. 96 (4). Neuropsychiatric Genetics, Wiley-Liss, pp 537 Versailles, 2000. [ Links ]

98. MUNDO E, WALKER M, CATE T, MACCIARDI F, KENNEDY JL: The Role of Serotonin Transporter Protein Gene in Antidepressant-Induced Mania in Bipolar Disorder. Arch Gen Psychiatry, 58:539-544, 2001. [ Links ]

99. MURPHY G, HOLLANDER S, RODRIGUES H, SCHATZBERG A: Effects of the serotonin transporter promoter polymorphism on paroxetine and mirtazapine efficacy and side effects in geriatric major depression. In: Hospital TZH (ed). Pharmacogenetics in Psychiatry Meeting. Vol. 1, pp green tab. New York, 2003a. [ Links ]

100. MURPHY GM Jr, HOLLANDER SB, RODRIGUES HE, KREMER C, SCHATZBERG AF: Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry , 61:1163-9, 2004. [ Links ]

101. MURPHY GM Jr, KREMER C, RODRIGUES HE, SCHATZBERG AF: Pharmacogenetics of Antidepressant Medication Intolerance. Am J Psychiatry , 160:1830-1835, 2003b. [ Links ]

102. NEBERT D, DIETER M: The evolution of drug metabolism. Pharmacology, 61:124-135, 2002. [ Links ]

103. NEER EJ: Heterotrimeric G proteins: organizers of transmembrane signals. Cell, 80:249-57, 1995. [ Links ]

104. NEMEROFF C, VALE W: The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry, 66:5-13, 2005. [ Links ]

105. NICULESCU AB 3rd, SEGAL DS, KUCZENSKI R, BARRETT T et al.: Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genomics, 4:83-91, 2000. [ Links ]

106. NIELSEN DA, JENKINS GL, STEFANISKO KM, JEFFERSON KK, GOLDMAN D: Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Research. Molecular Brain Research, 45:145-8, 1997. [ Links ]

107. NIERENBERG AA: Predictors of response to antidepressants general principals and clinical implications. Psychiatr Clin North Am , 26:345-352, 2003. [ Links ]

108. NOBILE M, CATALDO MG, GIORDA R, BATTAGLIA M et al.: A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol Psychiatry , 56:292-5, 2004. [ Links ]

109. OGILVIE AD, BATTERSBY S, BUBB VJ, FINK G et al.: Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet, 347:731-733, 1996. [ Links ]

110. O'REILLY RL, BOGUE L, SINGH SM: Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry , 36:467-71, 1994. [ Links ]

111. ORSINI A: Antidepressant responses and segregation analyses in affective families. In: Racagni G, Smeraldi E (eds). Anxious Depression: Assessment and Treatment. Raven Press, New York, 1987. [ Links ]

112. OVERSTREET D, GRIEBEL G: Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol, 497:49-53, 2004. [ Links ]

113. OZDEMIR V, TYNDALE R, REED K: Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol , 19:472-475, 1999. [ Links ]

114. PALOTAS A, PUSKAS L, KITAJKA K, PALOTAS M et al.: The effect of citalopram on gene expression profile of Alzheimer lymphocytes. Neurochem Res, 29:1563-1570, 2004. [ Links ]

115. PARE CM, REES L, SAINSBURY MJ: Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet, 2:1340-3, 1962. [ Links ]

116. PARK JW, KIM JS, LEE HK, KIM YI, LEE KS: Serotonin transporter polymorphism and harm avoidance personality in chronic tension-type headache. Headache, 44:1005-9, 2004. [ Links ]

117. PEREZ V, GILABERTE I, FARIES D, ALVAREZ E, ARTIGAS F: Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet, 349:1594-7, 1997. [ Links ]

118. PERLIS RH, MISCHOULON D, SMOLLER JW, WAN YJ et al.: Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry , 54:879-83, 2003. [ Links ]

119. PETERS EJ, SLAGER SL, MCGRATH PJ, KNOWLES JA, HAMILTON SP: Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry ,9:879-889, 2004. [ Links ]

120. POLLOCK BG, FERRELL RE, MULSANT BH, MAZUMDAR S et al.: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology , 23:587-590, 2000. [ Links ]

121. QUITKIN F, MCGRATH P, STEWART J, TAYLOR B, DF K: Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology , 15:390-394, 1996. [ Links ]

122. RAMAMOORTHY S, BAUMAN AL, MOORE KR, HAN H et al.: Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA, 90:2542-6, 1993. [ Links ]

123. RAUSCH JL, JOHNSON ME, FEI Y-J, LI JQ et al.: Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. Biological Psychiatry, 51:723-732, 2002. [ Links ]

124. REPPERT S, WEAVER D: Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol, 63:647-76, 2001. [ Links ]

125. REUL J, HOLSBOER F: Pathophysiology of depression and mechanisms of treatment. Dialogues Clinical Neuroscience , 4:31-46, 2002. [ Links ]

126. RIGAT B, HUBERT C, ALHENC-GELAS F, CAMBIEN F et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest, 86:1343-6, 1990. [ Links ]

127. RODEN D, GEORGE AJ: The genetic basis of variability in drug responses. Nat Rev Drug Discov, 1:37-44, 2002. [ Links ]

128. ROGERS D, HAGAN J: 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl) , 158:114-119, 2001. [ Links ]

129. ROUSSEVA A, HENRY C, Van den BULKE D, FOURNIER G et al.: Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J , 3:101-4, 2003. [ Links ]

130. RUJESCU D, GIEGLING I, SATO T, HARTMANN A, MOLLER H: Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis. Biol Psychiatry , 54:465-473, 2003. [ Links ]

131. SABOL SZ, HU S, HAMER D: A functional polymorphism in the monoamine oxidase A gene promoter. Human Genetic, 103:273-279, 1998. [ Links ]

132. SATO K, YOSHIDA K, TAKAHASHI H, ITO K et al.: Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology , 46:136-40, 2002. [ Links ]

133. SCHIEPERS O, WICHERS M, MAES M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry , 29:201-217, 2005. [ Links ]

134. SCHILDKRAUT JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry , 122:509-22, 1965. [ Links ]

135. SCHINKEL A, WAGENAAR E, MOL C, van DEEMTER L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest , 97:2517-2524, 1996. [ Links ]

136. SCHWARZ M, ACKENHEIL M: The role of substance P in depression: therapeutic implications. Dialogues Clinical Neuroscience , 4:21-29, 2002. [ Links ]

137. SERRETTI A, ARTIOLI P, LORENZI C, PIROVANO A et al.: The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol , 7:453-460, 2004a. [ Links ]

138. SERRETTI A, ARTIOLI P, ZANARDI R, LORENZI C et al.: Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl) , 174:504-511, 2004b. [ Links ]

139. SERRETTI A , BENEDETTI F, MANDELLI L, LORENZI C et al.: Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet , 121B:39-43, 2003a. [ Links ]

140. SERRETTI A, CALATI R, MANDELLI L, De RONCHI D: Serotonin transporter gene variants and behaviour: a comprehensive review. Current Drug Target, 7:1659-1669, 2006. [ Links ]

141. SERRETTI A, CUSIN C, BENEDETTI F, MANDELLI L et al.: Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet , 10:10, 2005. [ Links ]

142. SERRETTI A , FRANCHINI L, GASPERINI M, RAMPOLDI R et al.: Smeraldi E . Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatrica Scandinavica, 98:443-450 , 1998. [ Links ]

143. SERRETTI A, LORENZI C, CUSIN C, ZANARDI R et al.: SSRIs antidepressant activity is influenced by Gbeta3 variants. Eur Neuropsychopharmacol , 13:117-22, 2003b. [ Links ]

144. SERRETTI A, ZANARDI R, CUSIN C, ROSSINI D et al.: No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Research, 104:195-203, 2001a. [ Links ]

145. SERRETTI A, ZANARDI R, CUSIN C, ROSSINI D et al.: Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. European Neuropsychopharmacology , 11:375-380, 2001b. [ Links ]

146. SERRETTI A, ZANARDI R, ROSSINI D, CUSIN C et al.: Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular Psychiatry, 6:586-592, 2001c. [ Links ]

147. SEYMOUR P, SCHMIDT A, SCHULZ D: The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev, 9:57-96, 2003. [ Links ]

148. SIFFERT W, ROSSKOPF D, SIFFERT G, BUSCH S et al.: Association of a human G-protein beta3 subunit variant with hypertension. Nature Genetics, 18:45-8, 1998. [ Links ]

149. SKREBUHHOVA T, ALLIKMETS L, MATTO V. Effects of anxiogenic drugs in rat forced swimming test. Methods Find Exp Clin Pharmacol, 21:173-8, 1999. [ Links ]

150. SMERALDI E, ZANARDI R, BENEDETTI F, DIBELLA D et al.: Polymorphism Within the Promoter of the Serotonin Transporter Gene and Antidepressant Efficacy of Fluvoxamine. Molecular Psychiatry , 3:508-511, 1998. [ Links ]

151. STEEVES TD, ZHAO Y, SANGORAM AM, DU F et al.: Molecular cloning and characterization of the human clock gene: mexpression in the suprachiasmatic nuclei. Genomics, 57:198-200, 1999. [ Links ]

152. STEIGER H, JOOBER R, ISRAEL M, YOUNG SN et al.: The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. Int J Eat Disord, 37:57-60, 2005. [ Links ]

153. SUZUKI Y, SAWAMURA K, SOMEYA T: The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacoeconomics J, 4:283-286, 2004. [ Links ]

154. SZEGEDI A, RUJESCU D, TADIC A, MULLER MJ et al.: The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J , 5:49-53, 2005. [ Links ]

155. TAKAHASHI H, YOSHIDA K, ITO K, SATO K et al.: No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol , 12:477-81, 2002. [ Links ]

156. THIEBAUT F, TSURUO T, HAMADA H: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA , 84:7735-7738, 1987. [ Links ]

157. TRANTER R, O'DONOVAN C, CHANDARANA P, KENNEDY S: Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci , 27:241-247, 2002. [ Links ]

158. UHR M: ABCB1 genotyping is crucial for treatment with drugs that are P-glycoprotein substrates. Biol Psychiatry , 57:785, 2005. [ Links ]

159. VEEFKIND A, HAFFMANS P, HOENCAMP E: Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit, 22:202-208, 2000. [ Links ]

160. WALTHER DJ, PETER JU, BASHAMMAKH S, HORTNAGL H et al.: Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science, 299:76, 2003. [ Links ]

161. WEINSHILBOUM R: Inheritance and drug response. N Engl J Med, 348:529-537, 2003. [ Links ]

162. WEINSHILBOUM RM, OTTERNESS DM, SZUMLANSKI CL: Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol, 39:19-52, 1999. [ Links ]

163. WU S, COMINGS DE: A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet , 9:105-6, 1999. [ Links ]

164. WU WH, HUO SJ, CHENG CY, HONG C J, TSAI S J: Association Study of the 5-HT(6) Receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology , 44:172-5, 2001. [ Links ]

165. YAMADA M, YAMADA M, HIGUCHI T: Antidepressant-elicited changes in gene expression: remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog Neuropsychopharmacol Biol Psychiatry , 29:999-1009, 2005. [ Links ]

166. YANG-FENG TL, XUE FY, ZHONG WW, COTECCHIA S et al.: Chromosomal organization of adrenergic receptor genes. Proc Natl Acad Sci USA , 87:1516-20, 1990. [ Links ]

167. YEO A, BOYD P, LUMSDEN S, SAUNDERS T et al.: Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut, 53:1452-8, 2004. [ Links ]

168. YOSHIDA K, ITO K, SATO K, TAKAHASHI H et al.: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry , 26:383-6, 2002a. [ Links ]

169. YOSHIDA K, NAITO S, TAKAHASHI H, SATO K et al.: Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry , 26:1279-83, 2002b. [ Links ]

170. YOSHIDA K, TAKAHASHI H, HIGUCHI H, KAMATA M et al.: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry , 161:1575-80, 2004. [ Links ]

171. YU Y, TSAI S, HONG C, CHEN T, CHEN M, YANG C: Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology , 30:1719-23, 2005. [ Links ]

172. YU Y, TSAI S, LIOU Y, HONG C, CHEN T: Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur J Neuropsychopharmacol, 16:498-503, 2006. [ Links ]

173. YU YW, CHEN TJ, HONG CJ, CHEN HM, TSAI SJ: Association Study of the Interleukin-1beta (C-511T) Genetic Polymorphism with Major Depressive Disorder, Associated Symptomatology, and Antidepressant Response. Neuropsychopharmacology , 28:1182-5, 2003. [ Links ]

174. YU YW, TSAI SJ, CHEN TJ, LIN CH, HONG CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry , 7:1115-9, 2002 [ Links ]

175. ZANARDI R, BENEDETTI F, DIBELLA D, CATALANO M, SMERALDI E: Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clinical Psychopharmacology, 20:105-107, 2000. [ Links ]

176. ZANARDI R, SERRETTI A, ROSSINI D, FRANCHINI L et al.: Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological Psychiatry , 50:323-330, 2001. [ Links ]

177. ZANGEN A, NAKASH R, OVERSTREET DH, YADID G: Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology (Berl) , 155:434-9, 2001. [ Links ]

178. ZHANG X, GAINETDINOV R, BEAULIEU J-M, SOTNIKOVA T et al.: Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron, 45:45, 2005. [ Links ]

179. ZILL P BAGHAI TC, ENGEL R, ZWANZGER P et al.: The Beta-1-Adrenergic Receptor Gene in Major Depression: Influence on Antidepressant Treatment. In: Tsuang M (ed). Xth World Congress of Psychiatric Genetics. Vol. 114. Wiley-Liss New York, pp 777, Brussels, 2002. [ Links ]

180. ZILL P, BAGHAI TC, ZWANZGER P, SCHULe C et al.: Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport , 11:1893-7, 2000. [ Links ]

181. ZILL P, BUTTNER A, EISENMENGER W, MOLLER H et al.: Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: A post-mortem study. J Psychiatr Res , [Epub ahead of print], 2005. [ Links ]